Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
07 January 2002Website:
http://www.ipatherapeutics.comNext earnings report:
05 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 26 min agoDividend
Analysts recommendations
Institutional Ownership
IPA Latest News
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface (“API”) commercial rollout through expanding LENSai fe.
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate.
ImmunoPrecise Antibodies (NASDAQ: IPA ) stock is falling hard on Wednesday after the biotherapeutic company priced its shares in a public offering. This has ImmunoPrecise Antibodies offering 1.1 million shares of IPA stock for $1 per share.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time. The live and archived webcast of the presentation will be accessible from the company's website at https://ir.
What type of business is ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
What sector is ImmunoPrecise Antibodies in?
ImmunoPrecise Antibodies is in the Healthcare sector
What industry is ImmunoPrecise Antibodies in?
ImmunoPrecise Antibodies is in the Biotechnology industry
What country is ImmunoPrecise Antibodies from?
ImmunoPrecise Antibodies is headquartered in Canada
When did ImmunoPrecise Antibodies go public?
ImmunoPrecise Antibodies initial public offering (IPO) was on 07 January 2002
What is ImmunoPrecise Antibodies website?
https://www.ipatherapeutics.com
Is ImmunoPrecise Antibodies in the S&P 500?
No, ImmunoPrecise Antibodies is not included in the S&P 500 index
Is ImmunoPrecise Antibodies in the NASDAQ 100?
No, ImmunoPrecise Antibodies is not included in the NASDAQ 100 index
Is ImmunoPrecise Antibodies in the Dow Jones?
No, ImmunoPrecise Antibodies is not included in the Dow Jones index
When does ImmunoPrecise Antibodies report earnings?
The next expected earnings date for ImmunoPrecise Antibodies is 05 July 2024